Newborn blood spot screening for galactosemia, tyrosiemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease and severe combined immunodeficiency
Institute of Health Economics
Record ID 32016001098
English
Authors' objectives:
This STE report examines the safety, screening accuracy, therapeutic efficacy/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency), contextualized to the Alberta setting.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.ihe.ca/advanced-search/newborn-blood-spot-screening-for-galactosemia-tyrosiemia-type-i-homocystinuria-sickle-cell-anemia-sickle-cell-beta-thalassemia-sickle-cell-hemoglobin-c-disease-and-severe-combined-immunodeficiency
URL for additional information:
http://www.health.alberta.ca/initiatives/health-evidence-reviews-list.html
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Galactosemias
- Hemoglobin C Disease
- Hemoglobin SC Disease
- Homocystinuria
- Infant, Newborn
- Neonatal Screening
- Severe Combined Immunodeficiency
- beta-Thalassemia
Contact
Organisation Name:
Institute of Health Economics
Contact Address:
1200, 10405 – Jasper Avenue, Edmonton, AB T5J 3N4, Canada. Tel: +1 780 448 4881 Fax: +1 780 448 0018
Contact Name:
info@ihe.ca
Contact Email:
info@ihe.ca
Copyright:
Institute of Health Economics (IHE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.